In addition to the use of diuretics and SGLT-2 inhibitors, the ESC guidelines recommend the use of ACEi/ARNI/ARB, MRAs and beta blockers in patients with HFmrEF, while also emphasizing the use of finerenone and SGLT-2 inhibitors recommended to prevent HF and reduce the risk of HF hospitalization in patients with CKD and type 2 diabetes. Here, SLC5A2 is linked to hydrops fetalis.